Similarities and Differences in the Protein Composition of Cutaneous Melanoma Cells and Their Exosomes Identified by Mass Spectrometry.
LC-MS/MS
cancer
exosomes
extracellular vesicles
melanoma
proteomics
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
08 Feb 2023
08 Feb 2023
Historique:
received:
21
12
2022
revised:
31
01
2023
accepted:
05
02
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
26
2
2023
Statut:
epublish
Résumé
Intercellular transport of proteins mediated by extracellular vesicles (EVs)-exosomes and ectosomes-is one of the factors facilitating carcinogenesis. Therefore, the research on protein cargo of melanoma-derived EVs may provide a better understanding of the mechanisms involved in melanoma progression and contribute to the development of alternative biomarkers. Proteomic data on melanoma-derived EVs are very limited. The shotgun nanoLC-MS/MS approach was applied to analyze the protein composition of primary (WM115, WM793) and metastatic (WM266-4, WM1205Lu) cutaneous melanoma cells and exosomes released by them. All cells secreted homogeneous populations of exosomes that shared a characteristic set of proteins. In total, 3514 and 1234 unique proteins were identified in melanoma cells and exosomes, respectively. Gene ontology analysis showed enrichment in several cancer-related categories, including cell proliferation, migration, negative regulation of apoptosis, and angiogenesis. The obtained results broaden our knowledge on the role of selected proteins in exosome biology, as well as their functional role in the development and progression of cutaneous melanoma. The results may also inspire future studies on the clinical potential of exosomes.
Identifiants
pubmed: 36831440
pii: cancers15041097
doi: 10.3390/cancers15041097
pmc: PMC9954195
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : BioS Priority Research Area under the program "Excellence Initiative -Research University" at the Jagiellonian University in Krakow
ID : U1U/P03/DO/64.22
Références
Anticancer Res. 2015 Dec;35(12):6755-60
pubmed: 26637892
FEBS J. 2018 Mar;285(6):1033-1050
pubmed: 29399967
Exp Oncol. 2006 Jun;28(2):126-31
pubmed: 16837903
Br J Dermatol. 2017 Jul;177(1):134-140
pubmed: 28369739
J Extracell Vesicles. 2015 May 14;4:27066
pubmed: 25979354
Cancer Lett. 2016 Jul 1;376(2):318-27
pubmed: 27063098
Cell Death Dis. 2013 Nov 07;4:e914
pubmed: 24201813
Mol Cancer. 2022 Jan 18;21(1):20
pubmed: 35042524
Life Sci. 2018 Aug 15;207:395-411
pubmed: 29959030
Mol Cancer. 2013 Jun 14;12:62
pubmed: 23767874
Proteomes. 2019 May 13;7(2):
pubmed: 31086060
Pharmacol Ther. 2018 Aug;188:1-11
pubmed: 29476772
Cancer J. 2018 Mar/Apr;24(2):65-69
pubmed: 29601332
Anticancer Res. 2014 Dec;34(12):7091-6
pubmed: 25503136
J Exp Clin Cancer Res. 2018 Oct 5;37(1):245
pubmed: 30290833
Pigment Cell Melanoma Res. 2015 Jul;28(4):464-75
pubmed: 25950383
Int J Mol Sci. 2019 Aug 02;20(15):
pubmed: 31382537
Transl Oncol. 2022 Apr;18:101334
pubmed: 35093790
Mol Med. 2012 Dec 06;18:1269-80
pubmed: 22952058
Nat Commun. 2015 Apr 21;6:6919
pubmed: 25897521
Int J Mol Sci. 2020 Apr 22;21(8):
pubmed: 32331267
Front Immunol. 2021 Nov 10;12:766275
pubmed: 34858421
Clin Exp Metastasis. 2014 Oct;31(7):749-60
pubmed: 24997993
Dev Cell. 2022 Feb 7;57(3):329-343.e7
pubmed: 35085484
PLoS One. 2009;4(4):e5219
pubmed: 19381331
Cancer Lett. 2015 May 1;360(2):125-33
pubmed: 25661735
Oncogene. 2010 Nov 18;29(46):6115-24
pubmed: 20729912
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Biosensors (Basel). 2022 Jan 31;12(2):
pubmed: 35200349
J Extracell Vesicles. 2013 Jun 18;2:
pubmed: 24009892
Cancers (Basel). 2022 Jun 23;14(13):
pubmed: 35804857
Nature. 2015 Nov 19;527(7578):329-35
pubmed: 26524530
Proc Natl Acad Sci U S A. 2015 Apr 7;112(14):4441-6
pubmed: 25792458
Science. 2020 Feb 7;367(6478):
pubmed: 32029601
Melanoma Res. 2019 Oct;29(5):544-548
pubmed: 31116162
J Extracell Vesicles. 2021 Feb;10(4):e12063
pubmed: 33613873
Cancer Lett. 2014 May 28;347(1):29-37
pubmed: 24513178
Pharmaceutics. 2020 Sep 13;12(9):
pubmed: 32933147
Mol Cancer. 2014 Apr 26;13:88
pubmed: 24766647
J Immunol. 2007 Jun 1;178(11):6867-75
pubmed: 17513735
JCO Oncol Pract. 2022 May;18(5):335-351
pubmed: 35133862
Am J Pathol. 1993 Aug;143(2):528-37
pubmed: 8342600
J Transl Med. 2019 Jul 19;17(1):230
pubmed: 31324252
Lab Invest. 2009 Nov;89(11):1317-28
pubmed: 19786948
Br J Cancer. 2018 Mar 20;118(6):820-824
pubmed: 29509748
Mol Cell Biochem. 2013 Nov;383(1-2):13-20
pubmed: 23812844
J Immunother Cancer. 2022 Mar;10(3):
pubmed: 35273100
J Exp Med. 2019 May 6;216(5):1061-1070
pubmed: 30975894
Int J Mol Sci. 2022 Oct 01;23(19):
pubmed: 36232957
Tumour Biol. 2016 Nov;37(11):14577-14584
pubmed: 27612479
Nat Protoc. 2016 Dec;11(12):2301-2319
pubmed: 27809316
Front Cell Dev Biol. 2021 Sep 20;9:733627
pubmed: 34616739
Mol Carcinog. 2015 Jul;54(7):554-65
pubmed: 24347249
Cell Mol Life Sci. 2021 Mar;78(6):3057-3072
pubmed: 33237352
Nat Med. 2012 Jun;18(6):883-91
pubmed: 22635005
Cytokine. 2018 May;105:63-72
pubmed: 29459345
Mol Cancer. 2019 Mar 30;18(1):55
pubmed: 30925923
J Extracell Vesicles. 2022 Feb;11(2):e12197
pubmed: 35188342
Mol Syst Biol. 2014 Oct 30;10:757
pubmed: 25358341
J Exp Clin Cancer Res. 2018 Nov 19;37(1):278
pubmed: 30454024
J Clin Med. 2019 Mar 15;8(3):
pubmed: 30884760
Elife. 2018 Dec 11;7:
pubmed: 30526855
Proc Natl Acad Sci U S A. 1991 Jul 15;88(14):6028-32
pubmed: 2068080
Histochem Cell Biol. 2022 Feb;157(2):153-172
pubmed: 34837514
Cancer Res. 2011 Jun 1;71(11):3792-801
pubmed: 21478294
Crit Rev Oncog. 2015;20(3-4):301-14
pubmed: 26349421
Adv Exp Med Biol. 2015;867:115-24
pubmed: 26530363
J Natl Cancer Inst. 1985 Feb;74(2):283-9
pubmed: 3856042
Eur J Surg Oncol. 2012 Apr;38(4):281-5
pubmed: 22240030
Exp Cell Res. 2018 Oct 15;371(2):364-371
pubmed: 30149000
Nat Cancer. 2021 Dec;2(12):1387-1405
pubmed: 34957415
PLoS One. 2012;7(10):e46874
pubmed: 23056502